News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
423,378 Results
Type
Article (34516)
Company Profile (67)
Press Release (388784)
Multimedia
Podcasts (96)
Webinars (9)
Section
Business (115544)
Career Advice (1390)
Deals (24415)
Drug Delivery (126)
Drug Development (60601)
Employer Resources (111)
FDA (10442)
Job Trends (9296)
News (215846)
Policy (25895)
Tag
2027 Bio NC Standard (1)
2027 Genetown Standard (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (3)
Academia (1891)
Accelerated approval (43)
Adcomms (29)
Allergies (137)
Alliances (42536)
ALS (139)
Alzheimer's disease (1438)
Antibody-drug conjugate (ADC) (345)
Approvals (10626)
Artificial intelligence (432)
Autoimmune disease (187)
Automation (31)
Bankruptcy (239)
Best Places to Work (7762)
BIOSECURE Act (16)
Biosimilars (178)
Biotechnology (46)
Bladder cancer (137)
Brain cancer (70)
Breast cancer (516)
Cancer (4258)
Cardiovascular disease (345)
Career advice (1188)
Career pathing (29)
CAR-T (223)
CDC (69)
Cell therapy (619)
Cervical cancer (32)
Clinical research (52122)
Collaboration (1688)
Company closure (5)
Compensation (1176)
Complete response letters (81)
COVID-19 (2635)
CRISPR (77)
C-suite (576)
Cystic fibrosis (92)
Data (5543)
Decentralized trials (2)
Denatured (13)
Depression (123)
Dermatology (62)
Diabetes (447)
Diagnostics (3863)
Digital health (30)
Diversity (8)
Diversity, equity & inclusion (35)
Drug discovery (227)
Drug pricing (195)
Drug shortages (32)
Duchenne muscular dystrophy (243)
Earnings (44187)
Editorial (68)
Employer branding (18)
Employer resources (104)
Events (49925)
Executive appointments (528)
FDA (13106)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (13)
Frontotemporal dementia (26)
Funding (1107)
Gene editing (167)
Generative AI (45)
Gene therapy (572)
GLP-1 (1036)
Government (4478)
Grass and pollen (6)
Guidances (320)
Healthcare (11581)
HIV (67)
Huntington's disease (48)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (80)
Immunology and inflammation (215)
Immuno-oncology (73)
Indications (137)
Infectious disease (2959)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (132)
Intellectual property (183)
Interviews (247)
IPO (10616)
IRA (48)
Job creations (1828)
Job search strategy (998)
JPM (50)
Kidney cancer (13)
Labor market (64)
Layoffs (381)
Leadership (27)
Legal (7134)
Liver cancer (73)
Longevity (31)
Lung cancer (579)
Lymphoma (327)
Machine learning (39)
Management (33)
Manufacturing (741)
MASH (160)
Medical device (6147)
Medtech (6190)
Mergers & acquisitions (14777)
Metabolic disorders (1288)
mRNA (184)
Multiple sclerosis (135)
NASH (21)
Neurodegenerative disease (314)
Neuropsychiatric disorders (89)
Neuroscience (2553)
Neurotech (1)
NextGen: Class of 2026 (3749)
Non-profit (2826)
Now hiring (14)
Obesity (666)
Opinion (275)
Ovarian cancer (152)
Pain (150)
Pancreatic cancer (232)
Parkinson's disease (271)
Partnered (24)
Patents (373)
Patient recruitment (414)
Peanut (50)
People (27620)
Pharmaceutical (19)
Pharmacy benefit managers (20)
Phase 1 (15751)
Phase 2 (22672)
Phase 3 (18379)
Pipeline (6269)
Policy (316)
Postmarket research (1866)
Preclinical (6556)
Press Release (28)
Prostate cancer (216)
Psychedelics (51)
Radiopharmaceuticals (272)
Rare diseases (846)
Real estate (2665)
Recruiting (50)
Regulatory (18681)
Reports (27)
Research institute (1660)
Resumes & cover letters (212)
Rett syndrome (35)
RNA editing (13)
RSV (90)
Schizophrenia (147)
Series A (158)
Series B (123)
Service/supplier (3)
Sickle cell disease (72)
Special edition (17)
Spinal muscular atrophy (159)
Sponsored (32)
Startups (2044)
State (1)
Stomach cancer (14)
Supply chain (99)
Tariffs (86)
The Weekly (82)
Vaccines (1117)
Venture capital (87)
Weight loss (458)
Women's health (71)
Worklife (13)
Date
Today (89)
Last 7 days (609)
Last 30 days (2046)
Last 365 days (20005)
2026 (7526)
2025 (20091)
2024 (22580)
2023 (25476)
2022 (33712)
2021 (36280)
2020 (34395)
2019 (28268)
2018 (21535)
2017 (20522)
2016 (18927)
2015 (21725)
2014 (16137)
2013 (12995)
2012 (13786)
2011 (14549)
2010 (13211)
Location
Africa (603)
Alabama (56)
Alaska (3)
Arizona (135)
Arkansas (6)
Asia (27579)
Australia (4933)
California (8000)
Canada (2331)
China (959)
Colorado (321)
Connecticut (380)
Delaware (282)
Europe (66587)
Florida (1222)
Georgia (252)
Hawaii (4)
Idaho (30)
Illinois (597)
India (68)
Indiana (389)
Iowa (18)
Japan (426)
Kansas (83)
Kentucky (32)
Louisiana (21)
Maine (35)
Maryland (1114)
Massachusetts (5681)
Michigan (183)
Minnesota (285)
Mississippi (1)
Missouri (88)
Montana (21)
Nebraska (12)
Nevada (85)
New Hampshire (35)
New Jersey (2378)
New Mexico (17)
New York (2274)
North Carolina (955)
North Dakota (6)
Northern California (4090)
Ohio (221)
Oklahoma (10)
Oregon (14)
Pennsylvania (1620)
Puerto Rico (16)
Rhode Island (18)
South America (824)
South Carolina (42)
South Dakota (1)
Southern California (3127)
Tennessee (106)
Texas (1049)
United States (28169)
Utah (181)
Vermont (1)
Virginia (208)
Washington D.C. (44)
Washington State (616)
West Virginia (2)
Wisconsin (76)
Wyoming (2)
423,378 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
March 15, 2026
·
11 min read
Huntington’s disease
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval
Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more than 50%. Analysts say the decision to initiate a last-stage trial reflects a lack of confidence in an accelerated FDA nod.
April 29, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novartis’ sales dip as generics pressure intensifies, radioequivalents loom
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
April 28, 2026
·
2 min read
·
Tristan Manalac
Funding
Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases
George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.
April 27, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Novartis unveils North Carolina API plant as final piece of $23B US expansion
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.
May 1, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Novartis Keeps Deals Coming With $2B Excellergy Takeover
The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in children and adults.
March 27, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
March 24, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
Novartis will still be on the lookout for early-stage deals under $2 billion, and later-stage agreements around a product that could reach the market within five years, CEO Vas Narasimhan said Wednesday.
February 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
October 27, 2025
·
13 min read
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
March 20, 2026
·
2 min read
·
Tristan Manalac
1 of 42,338
Next
